DEA Blocks California Doc from Prescribing Controlled Drugs
Published Date: 4/1/2025
Notice
Summary
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Denied for Dr. Tran
The Drug Enforcement Administration denied Phong H. Tran, M.D.'s application for a DEA Certificate of Registration, Control No. W22138631C, in California and also denied any other pending application of his for additional registration in California. The Order is issued under 21 U.S.C. 823(g)(1) and 824(a)(5) and states it will be effective thirty days after publication in the Federal Register.
California Medical License Revoked
The Medical Board of California revoked Respondent's California medical license effective August 2, 2024, and California online records taken official notice show the license remains revoked. Because he is not licensed to practice medicine in California, DEA found he lacks the state authority required to obtain or maintain a DEA registration to handle controlled substances in that state.
Mandatory Exclusion From Federal Health Programs
The U.S. Department of Health and Human Services, Office of Inspector General excluded Respondent from participation in Medicare, Medicaid, and all federal health care programs effective September 20, 2022, for a period of twelve years. DEA treated that mandatory exclusion under 42 U.S.C. 1320a-7(a) and 21 U.S.C. 824(a)(5) as a separate, independent basis to deny his DEA registration application.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-05525, Notice of Intent To Rule on a Land Release Request for Disposal of Airport Property at Dinwiddie County Airport, Petersburg, VA
The Dinwiddie Airport wants to sell 44.24 acres of land near its main runway that’s no longer needed for flying. This change won’t mess with airport operations and could open up new uses for the land. People have until May 1, 2025, to share their thoughts before the FAA makes a final decision.
Next: 2025-05527, Baijes Bissonnet Pharmacy; Decision and Order
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.